{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:29:37Z","timestamp":1777922977667,"version":"3.51.4"},"reference-count":43,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>\n                    The antimicrobial activities of several \u03b2-lactam agents were tested by broth microdilution alone and in combination with a new polymyxin analog, SPR741 (at a fixed concentration of 8\u2009mg\/L), against a challenge set of clinical isolates (202\n                    <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                    and 221\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    isolates). Using Clinical and Laboratory Standards Institute (CLSI) or European Committee on Antimicrobial Susceptibility Testing (EUCAST) susceptibility criteria for each partner antibiotic, mecillinam\u2013SPR741, temocillin\u2013SPR741, and piperacillin\u2013tazobactam\u2013SPR741 combinations had susceptibility rates higher (85.6\u2013100.0%) than the respective agents tested alone (47.5\u201388.7%) against extended-spectrum \u03b2-lactamase (ESBL)-producing\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    . Temocillin\u2013SPR741 (97.8% susceptible) had MIC\n                    <jats:sub>50<\/jats:sub>\n                    (minimum inhibitory concentration) and MIC\n                    <jats:sub>90<\/jats:sub>\n                    results of 0.5 and 2\u2009mg\/L, respectively, against\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    carbapenemase (KPC)-producing\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    , 8- to 16-fold lower than temocillin alone (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 8\/16\u2009mg\/L; 65.2% susceptible). The mecillinam MIC\n                    <jats:sub>50<\/jats:sub>\n                    \/MIC\n                    <jats:sub>90<\/jats:sub>\n                    results dropped to 1\/4\u2009mg\/L (from 128\/&gt;256\u2009mg\/L when tested alone) against metallo-\u03b2-lactamase (MBL)-producing\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    . These MICs for mecillinam\u2013SPR741 resulted in a susceptibility rate of 96.9% versus 9.4% for mecillinam. In general, a decrease in MICs for \u03b2-lactams (MIC\n                    <jats:sub>90<\/jats:sub>\n                    , &gt;32\u2009mg\/L) in the presence of SPR741 was not observed against KPC-, MBL- or OXA-48-like-producing\n                    <jats:italic toggle=\"yes\">K. pneumoniae.<\/jats:italic>\n                    These study results indicate that some agents had a significant increase in\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    activity in the presence of SPR741 and could become potential strategic options for treating serious infections caused by multidrug-resistant Enterobacteriaceae.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2019.0198","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T14:05:55Z","timestamp":1570629955000},"page":"319-328","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of \u03b2-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens"],"prefix":"10.1177","volume":"26","author":[{"given":"Rodrigo E.","family":"Mendes","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Lister","sequence":"additional","affiliation":[{"name":"Spero Therapeutics Inc., Cambridge, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Cotroneo","sequence":"additional","affiliation":[{"name":"Spero Therapeutics Inc., Cambridge, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen","family":"Rubio","sequence":"additional","affiliation":[{"name":"Spero Therapeutics Inc., Cambridge, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,4,10]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-018-0336-y"},{"key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijantimicag.2018.04.001","article-title":"Molecular beta-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: efficacies analysed against susceptible and resistant subsets","volume":"52","author":"Mendes R.E.","year":"2018","unstructured":"Mendes R.E., , Castanheira M., , Woosley L.N, , Stone G.G, , Bradford P.A, , and Flamm R.K.. 2018. Molecular beta-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: efficacies analysed against susceptible and resistant subsets. Int. J. Antimicrob. Agents, 52:287\u2013292.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"e02447","DOI":"10.1128\/AAC.02447-16","article-title":"Molecular \u03b2-lactamase characterization of aerobic gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials for complicated intra-abdominal infections, with efficacies analyzed against susceptible and resistant subsets","volume":"61","author":"Mendes R.E.","year":"2017","unstructured":"Mendes R.E., , Castanheira M., , Woosley L.N, , Stone G.G, , Bradford P.A, , and Flamm R.K.. 2017. Molecular \u03b2-lactamase characterization of aerobic gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials for complicated intra-abdominal infections, with efficacies analyzed against susceptible and resistant subsets. Antimicrob. Agents Chemother. 61:e02447.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_5_5_2","first-page":"June","article-title":"Distribution of \u03b2eta-lactamase resistance genes and lineage background in clinical isolates producing extended-spectrum beta-lacatamases by high-resolution genomic analysis","author":"Mendes R.E.","year":"2018","unstructured":"Mendes R.E., , Jones R.N, , Woosley L.N, , Cattoir V., , and Castanheira M.. 2018. Distribution of \u03b2eta-lactamase resistance genes and lineage background in clinical isolates producing extended-spectrum beta-lacatamases by high-resolution genomic analysis. ASM Microbe 2018, Atlanta,, GA, June 7\u201311. no. Saturday-426.","journal-title":"ASM Microbe 2018, Atlanta,"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1222343"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01019-15"},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.medmal.2013.11.007","article-title":"Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge","volume":"44","author":"Nordmann P.","year":"2014","unstructured":"Nordmann P. 2014. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med. Mal. Infect. 44:51\u201356.","journal-title":"Med. Mal. Infect"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/14737167.2017.1358618","article-title":"Clinical and economic implications of urinary tract infections","volume":"17","author":"Steiger S.N.","year":"2017","unstructured":"Steiger S.N., , Comito R.R, , and Nicolau D.P.. 2017. Clinical and economic implications of urinary tract infections. Expert Rev. Pharmacoecon. Outcomes Res. 17:377\u2013383.","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"e00200","DOI":"10.1128\/AAC.00200-17","article-title":"Potentiation of antibiotic activity by a novel cationic peptide: potency and spectrum of activity of SPR741","volume":"61","author":"Corbett D.","year":"2017","unstructured":"Corbett D., , Wise A., , Langley T., , Skinner K., , Trimby E., , Birchall S., , Dorali A., , Sandiford S., , Williams J., , Warn P., , Vaara M., , and Lister T.. 2017. Potentiation of antibiotic activity by a novel cationic peptide: potency and spectrum of activity of SPR741. Antimicrob. Agents Chemother. 61:e00200.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1128\/AAC.01439-09","article-title":"A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane","volume":"54","author":"Vaara M.","year":"2010","unstructured":"Vaara M., , Siikanen O., , Apajalahti J., , Fox J., , Frimodt-Moller N., , He H., , Poudyal A., , Li J., , Nation R.L, , and Vaara T.. 2010. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob. Agents Chemother. 54:3341\u20133346.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/jac\/dkt039","article-title":"Novel derivatives of polymyxins","volume":"68","author":"Vaara M.","year":"2013","unstructured":"Vaara M. 2013. Novel derivatives of polymyxins. J. Antimicrob. Chemother. 68:1213\u20131219.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_5_13_2","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2018. M07Ed11E. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 11th ed. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_5_14_2","first-page":"April","article-title":"Safety of SPR741, a novel polymyxin potentiator, in healthy adutls receiving single- and multiple-dose intravenous administrations","author":"Eckburg P.B.","year":"2018","unstructured":"Eckburg P.B., , Farinola N., , Utley L., , Walpole S., , Keutzer T., , Kopp E., , Coleman S., , and Tomayko J.F.. 2018. Safety of SPR741, a novel polymyxin potentiator, in healthy adutls receiving single- and multiple-dose intravenous administrations. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID),, Madrid, April 21\u201324. Poster no. P2206.","journal-title":"European Congress of Clinical Microbiology and Infectious Diseases (ECCMID),"},{"key":"e_1_3_5_15_2","first-page":"April","article-title":"Determination of the pharmacokinetics of single (SAD) and multiple ascending doses (MAD) of SPR741 in healty volunteers","author":"Utley L.","year":"2018","unstructured":"Utley L., , Lister T., , Coleman S., , and Eckburg P.B.. 2018. Determination of the pharmacokinetics of single (SAD) and multiple ascending doses (MAD) of SPR741 in healty volunteers. European Congress of Clinical Micriology and Infectious Diseases (ECCMID),, Madrid, April 21\u201324. Poster no. P2233.","journal-title":"European Congress of Clinical Micriology and Infectious Diseases (ECCMID),"},{"key":"e_1_3_5_16_2","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2018. M100Ed28E. Performance Standards for Antimicrobial Susceptibility Testing. 28th Informational Supplement. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_5_17_2","unstructured":"British Society for Antimicrobial Chemotherapy (BSAC). 2014. Methods for antimicrobial susceptibility testing version 13. Available at http:\/\/bsac.org.uk\/wp-content\/uploads\/2014\/06\/BSAC-disc-susceptibility-testing-method-June-2014.pdf accessed July1 2018."},{"key":"e_1_3_5_18_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2018. Breakpoint tables for interpretation of MIC's and zone diameters. Version 8.0 January 2018. Available at www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_8.0_Breakpoint_Tables.pdf accessed January31 2018."},{"key":"e_1_3_5_19_2","unstructured":"British Society for Antimicrobial Chemotherapy (BSAC). 2014. Susceptiblity testing methodology-current version of breakpoint tables Version 13.0. Available at http:\/\/bsac.org.uk\/wp-content\/uploads\/2012\/02\/BSAC-Susceptibility-testing-version-131.pdf accessed July1 2018."},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1128\/AAC.45.12.3355-3361.2001","article-title":"CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop","volume":"45","author":"Poirel L.","year":"2001","unstructured":"Poirel L., , Naas T., , Le Thomas I., , Karim A., , Bingen E., , and Nordmann P.. 2001. CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Antimicrob. Agents Chemother. 45:3355\u20133361.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jac\/dkf240","article-title":"Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3","volume":"50","author":"Poirel L.","year":"2002","unstructured":"Poirel L., , Gniadkowski M., , and Nordmann P.. 2002. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. J. Antimicrob. Chemother. 50:1031\u20131034.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.femsle.2004.10.031","article-title":"Overexpression system and biochemical profile of CTX-M-3 extended-spectrum beta-lactamase expressed in Escherichia coli","volume":"241","author":"Perilli M.","year":"2004","unstructured":"Perilli M., , Ettorre D., , Segatore B., , Caporale B., , De Santis F., , Pochetti G., , Brigante G., , Mazza F., , Tavio M.M, , and Amicosante G.. 2004. Overexpression system and biochemical profile of CTX-M-3 extended-spectrum beta-lactamase expressed in Escherichia coli. FEMS Microbiol. Lett. 241:229\u2013232.","journal-title":"FEMS Microbiol. Lett"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijantimicag.2006.09.005","article-title":"Biochemical characterisation of the CTX-M-14 beta-lactamase","volume":"29","author":"Ishii Y.","year":"2007","unstructured":"Ishii Y., , Galleni M., , Ma L., , Frere J.M, , and Yamaguchi K.. 2007. Biochemical characterisation of the CTX-M-14 beta-lactamase. Int. J. Antimicrob. Agents, 29:159\u2013164.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"e56926","DOI":"10.1371\/journal.pone.0056926","article-title":"Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non-beta-lactam-beta-lactamase inhibitor","volume":"8","author":"Faheem M.","year":"2013","unstructured":"Faheem M., , Rehman M.T, , Danishuddin M., , and Khan A.U.. 2013. Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non-beta-lactam-beta-lactamase inhibitor. PLoS One, 8:e56926.","journal-title":"PLoS One"},{"key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fmolb.2018.00016","article-title":"Structural and mechanistic basis for extended-spectrum drug-resistance mutations in altering the specificity of TEM, CTX-M, and KPC beta-lactamases","volume":"5","author":"Palzkill T.","year":"2018","unstructured":"Palzkill T. 2018. Structural and mechanistic basis for extended-spectrum drug-resistance mutations in altering the specificity of TEM, CTX-M, and KPC beta-lactamases. Front. Mol. Biosci. 5:16.","journal-title":"Front. Mol. Biosci"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.medmal.2013.01.006","article-title":"Alternatives to carbapenems in ESBL-producing Escherichia coli infections","volume":"43","author":"Fournier D.","year":"2013","unstructured":"Fournier D., , Chirouze C., , Leroy J., , Cholley P., , Talon D., , Plesiat P., , and Bertrand X.. 2013. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med. Mal. Infect. 43:62\u201366.","journal-title":"Med. Mal. Infect"},{"key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10096-011-1183-4","article-title":"In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli","volume":"30","author":"Tarnberg M.","year":"2011","unstructured":"Tarnberg M., , Ostholm-Balkhed A., , Monstein H.J, , Hallgren A., , Hanberger H., , and Nilsson L.E.. 2011. In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli. Eur. J. Clin. Microbiol. Infect. Dis. 30:981\u2013987.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis"},{"key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/23744235.2015.1087648","article-title":"The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010-2011","volume":"48","author":"Zykov I.N.","year":"2016","unstructured":"Zykov I.N., , Sundsfjord A., , Smabrekke L., , and Samuelsen O.. 2016. The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010-2011. Infect. Dis. 48:99\u2013107.","journal-title":"Infect. Dis"},{"key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cmi.2015.05.022","article-title":"Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin","volume":"21","author":"Giske, C.G","year":"2015","unstructured":"Giske, C.G. 2015. Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin. Clin. Microbiol. Infect. 21:899\u2013905.","journal-title":"Clin. Microbiol. Infect"},{"key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dkn511","article-title":"Temocillin revived","volume":"63","author":"Livermore D.M.","year":"2009","unstructured":"Livermore D.M., , and Tulkens P.M.. 2009. Temocillin revived. J. Antimicrob. Chemother. 63:243\u2013245.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ebiom.2017.08.023","article-title":"Mecillinam\u2014reversion of resistance and how to test it","volume":"23","author":"Frimodt-Moller N.","year":"2017","unstructured":"Frimodt-Moller N. 2017. Mecillinam\u2014reversion of resistance and how to test it. EBioMedicine, 23:4\u20135.","journal-title":"EBioMedicine"},{"key":"e_1_3_5_32_2","first-page":"and","article-title":"In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp","author":"Woodford N.","year":"2014","unstructured":"Woodford N., , Pike R., , Meunier D., , Loy R., , Hill R., , and Hopkins K.L.. 2014. In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter, spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase. J. Antimicrob. Chemother. 69:564\u2013567.","journal-title":"and Enterobacter"},{"key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1128\/AAC.00290-09","article-title":"Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli","volume":"53","author":"Adams-Haduch J.M.","year":"2009","unstructured":"Adams-Haduch J.M., , Potoski B.A, , Sidjabat H.E, , Paterson D.L, , and Doi Y.. 2009. Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob. Agents Chemother. 53:2700\u20132701.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.348540"},{"key":"e_1_3_5_35_2","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1128\/AAC.47.12.3881-3889.2003","article-title":"Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2","volume":"47","author":"Yigit H.","year":"2003","unstructured":"Yigit H., , Queenan A.M, , Rasheed J.K, , Biddle J.W, , Domenech-Sanchez A., , Alberti S., , Bush K., , and Tenover F.C.. 2003. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2. Antimicrob. Agents Chemother. 47:3881\u20133889.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"e1004949","DOI":"10.1371\/journal.ppat.1004949","article-title":"Natural variants of the KPC-2 carbapenemase have evolved increased catalytic efficiency for ceftazidime hydrolysis at the cost of enzyme stability","volume":"11","author":"Mehta S.C.","year":"2015","unstructured":"Mehta S.C., , Rice K., , and Palzkill T.. 2015. Natural variants of the KPC-2 carbapenemase have evolved increased catalytic efficiency for ceftazidime hydrolysis at the cost of enzyme stability. PLoS Pathog. 11:e1004949.","journal-title":"PLoS Pathog"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389450117666160310144501"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00693-09"},{"key":"e_1_3_5_39_2","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1093\/jac\/dku204","article-title":"In vitro activity of mecillinam against Enterobacteriaceae with NDM-1 carbapenemase","volume":"69","author":"Marrs E.C.","year":"2014","unstructured":"Marrs E.C., , Day K.M, , and Perry J.D.. 2014. In vitro activity of mecillinam against Enterobacteriaceae with NDM-1 carbapenemase. J. Antimicrob. Chemother. 69:2873\u20132875.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.15-22.2004"},{"key":"e_1_3_5_41_2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jac\/dku524","article-title":"Heterogeneous hydrolytic features for OXA-48-like beta-lactamases","volume":"70","author":"Oueslati S.","year":"2015","unstructured":"Oueslati S., , Nordmann P., , and Poirel L.. 2015. Heterogeneous hydrolytic features for OXA-48-like beta-lactamases. J. Antimicrob. Chemother. 70:1059\u20131063.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_5_42_2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3109\/14756366.2012.702343","article-title":"OXA-162, a novel variant of OXA-48 displays extended hydrolytic activity towards imipenem, meropenem and doripenem","volume":"28","author":"Kasap M.","year":"2013","unstructured":"Kasap M., , Torol S., , Kolayli F., , Dundar D., , and Vahaboglu H.. 2013. OXA-162, a novel variant of OXA-48 displays extended hydrolytic activity towards imipenem, meropenem and doripenem. J. Enzyme Inhib. Med. Chem. 28:990\u2013996.","journal-title":"J. Enzyme Inhib. Med. Chem"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku465"},{"key":"e_1_3_5_44_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.20.1.38","article-title":"BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans","volume":"20","author":"Slocombe B.","year":"1981","unstructured":"Slocombe B., , Basker M.J, , Bentley P.H, , Clayton J.P, , Cole M., , Comber K.R, , Dixon R.A, , Edmondson R.A, , Jackson D., , Merrikin D.J, , and Sutherland R.. 1981. BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans. Antimicrob. Agents Chemother. 20:38\u201346.","journal-title":"Antimicrob. Agents Chemother"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2019.0198","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0198","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:36:02Z","timestamp":1777667762000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2019.0198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1089\/mdr.2019.0198"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2019.0198","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}